Ethical challenges of preexposure prophylaxis for HIV

JAMA

Volumn 308, Issue 9, 2012, Pages 867-868

  Jay, Jonathan S ^a   Gostin, Lawrence O ^a  

^a GEORGETOWN UNIVERSITY LAW CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ATTITUDE TO HEALTH; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EPIDEMIC; ETHICS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HIGH RISK PATIENT; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; JUSTICE; LAW; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PUBLIC HEALTH; RISK REDUCTION; SEX DIFFERENCE; SEXUAL BEHAVIOR; SHORT SURVEY; VIRUS TRANSMISSION; ARTICLE; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; DRUG COMBINATION; ECONOMICS; FEMALE; MALE; MEDICAL ETHICS; RISK; SERODIAGNOSIS; SOCIAL JUSTICE; UNSAFE SEX;

ANTI-RETROVIRAL AGENTS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUG COMBINATIONS; ETHICS, MEDICAL; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; MALE; MEDICALLY UNDERSERVED AREA; ORGANOPHOSPHORUS COMPOUNDS; RISK; SEXUAL BEHAVIOR; SOCIAL JUSTICE; UNSAFE SEX;

EID: 84865687603     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/2012.jama.10158     Document Type: Short Survey

References (10)

1. Prejean J, Song R, Hernandez A, et al HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
2. World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS Response: Epidemic Update And Health Sector Progress Towards Universal Access: Progress Report 2011. Geneva, Switzerland: WHO; 2011. http://whqlibdoc.who.int/ publications/2011/9789241502986-eng.pdf. Accessed July 24, 2012.
3. Baeten JM, Donnell D, Ndase P, et al; the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women [published online July 11, 2012]. N Engl J Med. 2012. doi:10.1056/NEJMoa1108524.
4. Anderson P, Liu A, Buchbinder S, et al; the iPrEx Study Team. Intracellular tenofovir-DP concentrations associated with PrEP efficacy in MSM from iPrEx. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 2012; Seattle, Washington.
5. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
6. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541-550.
7. Van Damme L, Corneli A, Ahmed K, et al; the FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women [published online July 11, 2012]. N Engl J Med. doi:10.1056/NEJMoa1202614.
8. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168- 1174.
9. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
10. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA. 2012;308(4):387-402.